#$11.6

[moneyhealthfinance-blog]

U.S. fund investors pull $11.6 billion from stocks in week: Lipper

U.S. fund investors pull $11.6 billion from stocks in week: Lipper

NEW YORK (Reuters) – Investors pulled $ 11.6 billion from U.S.-based equity funds during the latest week, marking the third straight week of withdrawals for those products, Lipper data showed on Thursday. Taxable bond funds attracted $ 3.5 billion during the week ended Wednesday, the research service’s data showed. Reporting by Trevor Hunnicutt … Reuters: Money

View On WordPress

[moneyhealthfinance-blog]

Sanofi is buying Bioverativ for $11.6 billion Sanofi's Chief Executive Officer Olivier BrandicourtBenoit Tessier/Reuters French drugmaker Sanofi is acquiring biotech company Bioverativ in a $ 11.6 billion deal. It's the biggest deal f... Business Insider

[moneyhealthfinance-blog]

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $ 11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases. Sanofi shares fell 3.4 percent by 0920 GMT, making the stock the worst performer on France’s benchmark CAC-40 index and several analysts deemed the deal…

View On WordPress

[moneyhealthfinance-blog]

Healthcare group Sanofi agrees to buy U.S. peer Bioverativ for $11.6 billion

PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for $ 11.6 billion, in a deal which Sanofi said would boost its earnings and strengthen its presence in the field of treatments for rare diseases. Sanofi has agreed to buy all of the outstanding shares of Bioverativ for $ 105 per share in cash, marking a premium of 64 percent to Bioverativ’s closing price on…

View On WordPress

[moneyhealthfinance-blog]

Sanofi confirms deal to buy Bioverativ for $11.6 billion © Reuters. French multinational pharmaceutical company SANOFI logo seen at their headquater in Paris PARIS (Reuters) - French healthcare group Sanofi (PA:) has agreed to buy U.S.

[moneyhealthfinance-blog]

Sanofi confirms deal to buy Bioverativ for $11.6 billion

PARIS (Reuters) – French healthcare group Sanofi has agreed to buy U.S. peer Bioverativ for $ 11.6 billion, in a deal which Sanofi said would boost its earnings and strengthen its presence in the field of treatment for rare diseases. Sanofi has agreed to buy all of the outstanding shares of Bioverativ for $ 105 per share in cash, marking a premium of 64 percent to Bioverativ’s closing price on…

View On WordPress